Rapt Therapeutics Inc. has announced a regulatory issue concerning its compliance with Nasdaq Listing Rule 5810(b). The company disclosed that it received a notice indicating a deficiency, which prompted the filing of a Form 8-K under Item 3.01. This filing is part of the company's obligation to publicly announce the deficiency within four business days of receiving the notice. Further details on the nature of the deficiency were not disclosed in the announcement. The company will need to address this issue to ensure continued compliance with Nasdaq's listing requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.